Clerkenwell Health

The company recruits participants for research studies on depression, anxiety, PTSD, and other brain, mind, and nervous system conditions.

Clerkenwell Health opens the UK’s first fully NHS-embedded commercial research site focused on brain and mental health conditions. The initiative integrates clinical trials directly into NHS infrastructure, aiming to accelerate research for neurological and psychiatric disorders. The site marks a collaboration between private and public healthcare sectors to streamline mental health treatment development.

Sep 2025Drug Discovery World (DDW)News article

Clerkenwell Health is recruiting volunteers for clinical trials exploring psychedelics as potential treatments for complex mental health conditions. The initiative aims to assess efficacy in addressing disorders through controlled research settings. Participants will contribute to studies evaluating novel therapeutic approaches in psychiatry.

Nov 2023Yahoo FinanceNews article

Clerkenwell Health secures £2.1 million in seed funding to advance its operations as a psychedelic-focused clinical research organization. The London-based startup now has a total of £2.5 million in funding to support its work in testing emerging psychedelic treatments. The funds will help establish its infrastructure and accelerate research efforts in the field.

Oct 2022TechCrunchNews article

A Bristol-based paediatric nurse, who has battled depression since age 12, participates in a UK psychedelic drug trial after conventional antidepressants worsened side effects like weight gain, nightmares, and sleep paralysis. The clinic explores alternative treatments for severe depression and anxiety resistant to traditional medications. Participants like Ali, whose condition deteriorated following a friend’s death, seek non-pharmacological interventions.

Sep 2022The i PaperNews article